Advocacy intelligence hub — real-time data for patient organizations
Fondazione Italiana Linfomi - ETS
Fudan University — PHASE3
Jonathan Brammer — PHASE2
Baylor College of Medicine — PHASE1
Memorial Sloan Kettering Cancer Center — PHASE1
New York Medical College — PHASE2
Eastern Cooperative Oncology Group — PHASE3
Yale University — PHASE2
CRISPR Therapeutics — PHASE1, PHASE2
Mayo Clinic — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Xalkori
(crizotinib)Orphan drugPfizer, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 ...
Adcetris
(brentuximab vedotin)Orphan drugstandardSeagen Inc.
CD30-directed Immunoconjugate [EPC]
12.1 Mechanism of Action CD30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of sALCL cells and on Hodgkin R...
Browse all ALK-negative anaplastic large cell lymphoma news →
Alex F Herrera
City of Hope Medical Center
Steven Horwitz, MD
Memorial Sloan Kettering Cancer Center
Premal Lulla, MD, M.D
Baylor College of Medicine
📍 HOUSTON, TX
Ann (Annie) W Silk
Dana-Farber - Harvard Cancer Center LAO
📍 Los Angeles, California
Matthew A Lunning, D.O
University of Nebraska
📍 OMAHA, NE
Bistol-Myers Squibb
Bristol-Myers Squibb
View all ALK-negative anaplastic large cell lymphoma specialists →